The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Teresa Bernal et al.|Blood|2023Cited by 15
Enhanced Validation of the <i>FLT3</i>-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in <i>FLT3-ITD</i> Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2024Cited by 3
Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2023Cited by 1
Molecular Mechanisms of Quizartinib Response in <i>FLT3-ITD</i> Negative AML: An Updated Analysis from the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, David Martínez‐Cuadrón et al.|Blood|2024Cited by 1